CCO Treatment Updates
Advances in Lymphoproliferative Disease: From Molecular Pathogenesis to Multitargeted Treatment
Modules and Slidesets
Pathogenesis and Progression of Lymphoproliferative Disease: Evolving Concepts
|
Program Director: Alexandra M. Levine, MD, MACP
- Alexandra M. Levine, MD, MACP
|
|
|
Alexandra M. Levine, MD, discusses evolving concepts in the pathogenesis of lymphoproliferative disease, including chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt’s lymphoma, diffuse large B-cell lymphoma, and germinal center cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define the unique characteristics of non-Hodgkin’s lymphomas
- Recall the relevant pathophysiology of lymphoproliferative diseases when designing a treatment strategy
- Cite current evidence when selecting optimal treatment for patients with non-Hodgkin’s lymphomas to improve patient outcomes and quality of life
|
Slideset: Pathogenesis and Progression of Lymphoproliferative Disease: Evolving Concepts
 |
|
Downloadable slideset focused on the pathogenesis, disease progression, and molecular markers involved in lymphoproliferative disorders.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.83 MB
| Date posted: 9/11/2008
|
Cytotoxic Chemotherapy in a Time of Change
|
Program Chair: Alexandra M. Levine, MD, MACP
|
|
Julie M. Vose, MD, reviews current clinical trial data and novel chemotherapeutic agents used in the treatment of lymphoproliferative disorders
Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite purine analogues used in the treatment of leukemias and lymphomas
- Describe the use of alkylating agents in the treatment of patients with leukemias or lymphomas
- Identify recent clinical trial data regarding antifolates in the clinical management of leukemias and lymphomas
- Discuss liposomal delivery of agents used to treat lymphoproliferative disorders
|
Slideset: Cytotoxic Chemotherapy in a Time of Change
 |
|
Downloadable slideset focused on current clinical trial data and novel chemotherapeutic agents used in the treatment of lymphoproliferative disorders
Format: Microsoft PowerPoint (.ppt) |
File size: 1.63 MB
| Date posted: 7/15/2008
|
Monoclonal Antibodies in Lymphoproliferative Disorders: From Rationale to Results
|
Program Director: Alexandra M. Levine, MD, MACP
- Jonathan W. Friedberg, MD
|
|
|
Jonathan W. Friedberg, MD, reviews the clinical use of currently available and investigational monoclonal antibodies in the treatment of follicular lymphoma and other non-Hodgkin’s lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the use of rituximab alone and in combination with chemotherapy for the treatment of non-Hodgkin’s lymphomas
- Cite novel antibodies in clinical development for the treatment of non-Hodgkin’s lymphomas
- Explain differences between the treatment of patients with and without previous treatment for non-Hodgkin’s lymphomas
|
Slideset: Monoclonal Antibodies in Lymphoproliferative Disorders: From Rationale to Results
 |
|
Downloadable slideset focused on the clinical use of currently available and investigational monoclonal antibodies for treating follicular lymphoma and other non-Hodgkin’s lymphomas.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.24 MB
| Date posted: 8/28/2008
|
Mechanism-Based Therapies for the Treatment of Lymphoid Leukemias
|
Program Director: Alexandra M. Levine, MD, MACP
- Michael J. Keating, MB BS
|
|
|
Michael J. Keating, MB BS, reviews current clinical trial data and novel mechanism-based therapies for use in the treatment of lymphoid leukemias, including chronic lymphocytic leukemia and Richter’s syndrome.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite novel mechanism-based therapies used in the treatment of chronic lymphocytic leukemia
- Describe efficacy and safety results from clinical trials enrolling patients with chronic lymphocytic leukemia
- Discuss current treatment options used in patients with chronic lymphocytic leukemia
|
Slideset: Mechanism Based Therapies for the Treatment of Lymphoid Leukemias
 |
|
Downloadable slideset focused on current clinical trial data and novel mechanism-based therapies for use in the treatment of lymphoid leukemias, including chronic lymphocytic leukemia and Richter’s syndrome.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.52 MB
| Date posted: 8/8/2008
|
Advances in Targeted Therapies for the Treatment of Non-Hodgkin’s Lymphomas
|
Program Chair: Alexandra M. Levine, MD, MACP
|
|
Andre Goy, MD, MPH, reviews the use of currently available and emerging novel targeted agents in the treatment of follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin’s lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe standard and emerging treatment options for indolent and aggressive lymphomas
- Recall clinical trial data regarding the use of monoclonal antibodies in the treatment of non-Hodgkin’s lymphomas
- Summarize the use of radioimmunotherapy in the treatment of lymphomas
- Cite small-molecule targeted agents used to treat lymphomas
|
Slideset: Advances in Targeted Therapies for the Treatment of Non-Hodgkin’s Lymphomas
 |
|
Downloadable slideset focused on currently available and emerging novel targeted agents in the treatment of follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin’s lymphomas.
Format: Microsoft PowerPoint (.ppt) |
File size: 1,018 KB
| Date posted: 7/30/2008
|
Debate Session – Strategic Approaches to Therapy: Advances and Challenges
|
Program Director: Alexandra M. Levine, MD, MACP
- Michael J. Keating, MB BS
- Julie M. Vose, MD
- Alexandra M. Levine, MD, MACP
|
|
|
Alexandra M. Levine, MD, Michael J. Keating, MB BS, and Julie M. Vose, MD, discuss current strategies and challenges in the management of chronic lymphocytic leukemia, follicular lymphoma, and Richter’s syndrome.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite the rationale for treatment selection to optimize outcomes in patients with chronic lymphocytic leukemia or indolent lymphoma
- Identify the appropriate time to employ radioimmunotherapy as treatment for follicular lymphoma
- Define the diagnostic characteristics of Richter’s syndrome and specify the optimal treatment strategies for this condition based on current evidence
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|